Navigation Links
Martek Announces Settlement of Patent Dispute with Capsugel France
Date:9/10/2009

COLUMBIA, Md., Sept. 10 /PRNewswire-FirstCall/ -- DHA omega-3 innovator and maker of the life'sDHA(TM) brand, Martek Biosciences Corporation (Nasdaq: MATK), announced today it has resolved a patent dispute with Capsugel France. The resolution follows Martek's November 2008 action for infringement filed in the High Court of Strasbourg, France.

As a result of this settlement agreement between Martek and Capsugel France, Capsugel and all of its affiliates have agreed to purchase all of their algal DHA exclusively from Martek for the life of the patent in question. Additionally, Martek and Capsugel will develop a product containing Martek's algal DHA in Capsugel's proprietary Licaps(R) liquid-filled hard capsules.

This settlement agreement between Martek and Capsugel does not include Martek's action against Lonza Ltd AG, which continues.

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces life'sDHA, a sustainable and vegetarian source of DHA omega-3, for use in foods, beverages, infant formula, and supplements, and life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, for use in infant formula and growing-up milks. For more information on Martek Biosciences, visit http://www.martek.com/. For a complete list of life'sDHA or life'sARA products, visit http://www.lifesdha.com/.

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2008 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

    Contact:

    Kyle Stults
    Investor Relations, Martek
    (410) 740-0081
    investors@martek.com

    Cassie France-Kelly
    Public Relations, Martek
    (443) 542-2116
    media@martek.com


'/>"/>
SOURCE Martek Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Martek to Announce Third Quarter 2007 Results on September 5, 2007
2. Martek to Present at Upcoming UBS Conference
3. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
4. Martek Announces Settlement of OmegaTech Milestone Litigation
5. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
6. European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed
7. Martek to Present at Upcoming ThinkEquity Partners Conference
8. Martek Announces Fourth Quarter and FY 2007 Financial Results
9. Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea
10. Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer
11. Challenge Spreadable Butter Now Features Marteks lifesDHA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):